Syndax Pharmaceuticals, Inc. Payments for (Proceeds from) Deposit on Loan
Syndax Pharmaceuticals, Inc. (SNDX) reported Payments for (Proceeds from) Deposit on Loan of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromDepositOnLoan · last filed 2025-03-03
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for the quarter ending 2023-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for the quarter ending 2022-12-31 was -$2.00K.
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for the quarter ending 2021-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for fiscal 2024 was $0.00.
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for fiscal 2022 was $21.00M.
- Syndax Pharmaceuticals, Inc. payments for (proceeds from) deposit on loan for fiscal 2021 was $0.00.
| Period end | Payments for (Proceeds from) Deposit on Loan 3 month | Payments for (Proceeds from) Deposit on Loan 9 month | Payments for (Proceeds from) Deposit on Loan 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $21.00M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $21.00M 10-Q · filed 2023-11-02 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |